Quarterly results were in line and the Alina EU approval is a positive signal for the proprietary device strategy, but the near-term financial benefit is modest. Monitor for Alina revenue ramp and US approvals in H2 2026; BDS margin trajectory in Q3/Q4 will indicate whether the Latina/Fishers ramp is on track. The negative free cash flow and elevated net debt warrant caution despite accretive divestiture.
Price Chart
Executive Summary
Stevanato Group reported Q2 2026 revenue of €302 million (+8% YoY) and adjusted EBITDA of €78.7 million (+21%), in line with expectations. The company updated FY2026 guidance to revenue of €1.26B–€1.28B and adjusted diluted EPS of €0.60–€0.62, reflecting the Balda C. Brewer divestiture and modest organic strength. The key positive was the Alina pen platform receiving European approval for a liraglutide therapy, marking a commercial milestone for a proprietary device.
Key Facts
- Q2 2026 revenue €302M (+8% YoY), BDS +9%, Engineering –2%.
- Adjusted EBITDA €78.7M (+21% YoY); adjusted EBITDA margin 26% (+280 bps).
- High-value solutions revenue grew 16% to €135.9M, 45% of total revenue.
- Divested Balda C. Brewer (€30M FY2026 revenue); one-time expense of €12.2M recorded.
- Alina variable-dose pen platform approved in EU for liraglutide therapy; US approval expected H2 2026.
- FY2026 guidance: revenue €1.26B–€1.28B; adjusted EBITDA €335M–€345.2M; adj. diluted EPS €0.60–€0.62.
- Net debt €360.3M; free cash flow –€32M in Q2; full-year FCF guided to breakeven to +€20M.
- GLP-1 revenue was ~22–23% of total; biologics ~42% of BDS segment revenue.
Financial Impact
Revenue +8% to €302M, adjusted EBITDA +21% to €78.7M, guided FY revenue ~€1.27B midpoint, adj. diluted EPS €0.60–€0.62.
Risk Factors
- Free cash flow negative at –€32M in Q2; full-year guidance only breakeven to +€20M.
- Engineering segment decline and elongated sales cycles remain a headwind.
- Higher tax rate (~28.2% adjusted) and no Italian tax incentive weigh on EPS.
- Distribution of One-time transaction costs and startup expenses may distort reported margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-337907 |
| Document: transcript_aug_4_2026.htm | 0001193125-26-337907 |
| Document: 0001193125-26-337907-index-headers.html | 0001193125-26-337907 |
| Document: 0001193125-26-337907-index.html | 0001193125-26-337907 |
| Document: 0001193125-26-337907.txt | 0001193125-26-337907 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | Insider Cluster | $21.05 $20.24 | ▼ −3.85% | ▼ −2.79% | $19.88 (−5.56%) |
Aug 6, 2026 11w ago | 6-K | $20.27 $20.51 | ▲ +1.18% | ▲ +1.58% | $19.88 (−1.92%) |
Aug 4, 2026 11w ago | 6-K | $20.10 $20.73 | ▲ +3.13% | ▲ +3.74% | $19.88 (−1.09%) |
May 11, 2026 24w ago | 6-K | $18.28 $18.03 | ▼ −1.34% | ▼ −1.04% | $19.88 (+8.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers